Inner nuclear layer (INL) and outer nuclear layer (ONL) abnormalities may be novel biomarkers to measure neurodegeneration in individuals with progressive multiple sclerosis (PMS).
Why this matters
Some individuals with multiple sclerosis can experience PMS where disability accumulates at the onset of disease. A lack of reliable biomarkers which monitor neurodegeneration has hindered development of therapies. The results of this study suggest that incorporating optical coherence tomography (OCT) as an outcome would be beneficial in clinical trial design.